Microvascular Complications in Diabetic Erectile Dysfunction: Do we need other alternatives? by Vardi, Yoram
Microvascular Complications in Diabetic
Erectile Dysfunction




tile dysfunction (ED) and its ad-
verse effects on the quality of life of
men and their partners have encouraged
researchers to look for new solutions for
treating and curing ED. The introduction
of phosphodiesterase type 5 inhibitors to
treatEDin1998wasrevolutionaryinthat
it heralded the onset of a new era of effec-
tive and safe treatment for restoring male
sexual function.
Today, PDE5 inhibitors are used as
ﬁrst-line therapy for the management of
EDirrespectiveofitsetiology.Despitethe
fact that millions of men with ED world-
wide have been treated successfully with
these drugs, several questions regarding
their efﬁcacy and safety and the high
dropout rate in men to whom these med-
ications are prescribed remain unan-
swered. This is especially evident in
diabetes because the frequency of ED in
men with diabetes is higher than that of
the general population. In fact, the fre-
quency of ED in diabetic men has been
reportedtobeashighas75%inmenwith
longstanding disease (1–3). In contrast to
the high efﬁcacy rate of PDE5 inhibitors
in the general population (70–89%), just
over 50% of diabetic men with ED re-
spond favorably to these drugs (4). Im-
paired neural and penile vascular
functions are believed to be the main rea-
sons for the high incidence of ED in men
with diabetes, and the underlying causes
of this drug resistance are not fully
understood.
RecentdataindicatethatPDE5inhib-
itors have beneﬁcial effects in other
chronic diseases. Sildenaﬁl has been ap-
proved recently for the treatment of idio-
pathic pulmonary hypertension (5).
Lately,severalreportshavesuggestedthat
PDE5 inhibitors may improve arterial
function (6–9). Moreover, improvement
of lower urinary tract symptoms in pa-
tients with benign prostatic hyperplasia
has also been reported (10). Finally, the
results of research in the basic sciences
and clinical studies have yielded promis-
ing therapeutic results regarding the con-
tinual use of PDE5 inhibitors to treat a





All three PDE5 inhibitors (sildenaﬁl,
tadalaﬁl, and vardenaﬁl) have undergone
extensive evaluation in patients with ED
secondarytoeitherhypertension,periph-
eral vascular disease, nerve injury, diabe-
tes, or postradical pelvic surgeries. The
response rate of ED patients with these
conditions is impressive and can be as
high as 60–70%. Diabetic men have dis-
playedimpairedresponseratesinallther-
apeutic trials (11,12). The major
predictors for treatment success have
been identiﬁed as having few diabetic
complications and good glycemic control
(13). Patients with ED secondary to radi-
cal prostatectomy is another difﬁcult-to-
treat group of patients with ED and are of
major interest for urologists.
Differences in pharmacokinetic
proﬁles
Several recent publications have empha-
sized that the onset time of response after
the oral administration of sildenaﬁl,
tadalaﬁl,andvardenaﬁlmaybeasshortas
15min(14–16).However,suchdatamay
lead to mistreatment because the onset of
response in the majority of the patients
occurs usually when the maximum
plasma concentration is reached (1h
for sildenaﬁl and vardenaﬁl and 2 h for
tadalaﬁl). Furthermore, patients taking
PDE5 inhibitors should be told to avoid
fatty meals when taking these drugs
orally,especiallysildenaﬁlandvardenaﬁl,
to get a satisfying erection.
Thedurationofactionofthedifferent
PDE5 inhibitors has been well docu-
mented in all premarketing clinical trials.
Initially, it was reported that sildenaﬁl
and vardenaﬁl have a short duration of
action (maximum 4 h). Clinical experi-
encehasnowshownthattheirdurationof
action is longer and that it may be as long
as 8–12 h (17). On the other hand, the
duration of action of tadalaﬁl was reported
initially to be 24 h. Consecutive trials and
clinicalusehaveshownaconsistentefﬁcacy
of tadalaﬁl for up to 36 h (18).
It is quite common that physicians
prescribe drugs to their patients without
any explanation. When prescribing PDE5
inhibitors, the importance of taking med-
ication on an empty stomach and timing
between drug intake and intercourse, as
well as the need for sexual stimulation to
get an erectile response, are crucial issues
that need to be explained to patients to
ensuredrugefﬁcacy.Theresultsofseveral
studies have identiﬁed inappropriate in-
structions and lack of follow-up as the
most common causes for the poor re-
sponse to PDE5 inhibitors or poor drug
compliance.Ithasbeenreportedthat30–
50%oftheinitialnonresponderstoPDE5
inhibitors can be converted to responders
when patients are given proper instruc-
tions on how to use the drug (19,20).
Safety
PDE5 inhibitors are safe drugs, and the
main contraindications for their use is the
concomitant use of nitrates and use in pa-
tientswithretinitispigmentosa.Although
several cardiovascular safety issues have
been raised since their clinical introduc-
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and clinical pharmacologic surveillance
data have demonstrated no increase in
myocardial infarction rates in patients
takingtheseagentscomparedwiththeex-
pected rates in age-matched populations
(21,22). Furthermore, the results of nu-
merous studies have proven not only the
cardiovascular safety of PDE5 inhibitors,
but even possible cardiovascular beneﬁts
(7,8).
One important safety issue is the co-
administration of PDE5 inhibitors with
-adrenoceptor blockers in patients with
benign prostatic hyperplasia. All PDE5
inhibitors appear to have some interac-
tion with -adrenoceptor blockers with
respect to lowering blood pressure, but
co-administration rarely results in clinically
signiﬁcant orthostatic hypotension (23).
Recently,theU.S.FoodandDrugAd-
ministration (FDA) alerted health provid-
ers about a possible association between
the use of PDE5 inhibitors and nonar-
teritic anterior ischemic optic neuropathy
(NAION) in response to a small number
(50 cases) of postmarketing reports of
vision loss in men taking PDE5 inhibitors
(24). Based on currently available data, it
is recommended that patients with a his-
toryofmono-ocularNAIONbecautioned
that the administration of PDE5 inhibi-
tors may increase the risk of NAION in
the fellow eye. Patients who have risk fac-
tors for the development of NAION
should be referred to an ophthalmologist
before being prescribed PDE5 inhibitors.
Furthermore, any man taking a PDE5 in-
hibitor who develops visual problems
should stop taking the PDE5 inhibitor




PDE5 INHIBITORS— Since silde-
naﬁl was ﬁrst introduced to treat ED, on-
demand administration was the
recommended mode of its administration
and this became the standard. When
newer PDE5 inhibitors entered the mar-
ket,thesameon-demandmodeofadmin-
istrationwasmaintained.Inanattemptto
improve efﬁcacy, particularly in patients
with severe ED, results of several inde-
pendentstudieshaveshownthatdailyuse
of a PDE5 inhibitor may play a role not
only in improving their efﬁcacy, but also
in curing ED (25) and that the long-term
administration of PDE5 inhibitors is ben-
eﬁcialfortheearlyrehabilitationofpenile
endothelial function after radical prosta-
tectomy(26).Moreover,currentdatasug-
gest that endothelial dysfunction is
common to both ED and cardiovascular
diseases (27). Endothelial dysfunction re-
sults in reduced ability of the endothelial
cells to release vasorelaxants, such as ni-
tric oxide (28,29). Consequently, the
ability of the arteriolar smooth muscle
cells to relax efﬁciently is impaired, and
aninadequateincreaseinlocalbloodﬂow
ensues. The administration of PDE5 in-
hibitors has been reported to improve en-
dothelium-dependent, ﬂow-mediated
vasodilation in smokers and in patients
with diabetes or chronic heart failure
(30,31). De Young et al. (32) have shown
recentlythatdailyadministrationofPDE5
inhibitors can lead to improvements in
the functioning of the erectile tissue in a
diabetic animal model. The results of
other studies have established that phys-
iological and cellular changes that occur
in ED can be reversed with long-term ad-
ministration of PDE5 inhibitors. In addi-
tion, Ayala et al. reported that chronic
inhibition of PDE5 in high fat-fed con-
scious mice counters the effects of the
high-fat diet–induced endothelial dys-
function and insulin resistance by im-
proving energy balance and enhancing
insulin action in vivo (33).
Emerging clinical evidence indicates
that this beneﬁcial chronic effect of PDE5
inhibitors on endothelial and erectile
function may also occur in humans.
Chronic therapy with tadalaﬁl has been
reported to improve endothelial function
and erectile function in ED patients with
cardiovascular risk factors (28,34). Ini-
tially, long-term use of PDE5 inhibitors
was recommended in patients who did
not respond when treated on-demand. In
this setting, McMahon (35) reported that
a signiﬁcant proportion of patients who
were previously considered as nonre-
sponderstoon-demandtadalaﬁlandthen
prescribed 10 mg tadalaﬁl every 3 days
were able to achieve intercourse 58% of
the time. In another study, Mirone et al.
(36)comparedtheresponseof4,262men
with ED and cardiovascular risk factors
that were using either tadalaﬁl on-
demand or in a daily regimen and re-
ported that those men with ED who used
tadalaﬁl on scheduled regimen had more
attempted sexual encounters than the on-
demandgroup.Inaddition,theauthorsof
both studies reported an excellent safety
proﬁle of tadalaﬁl in the chronically
treated group.
Another advantage of daily adminis-
tration of a PDE5 inhibitor, at least for
somecouples,isnotonlytheefﬁcacypro-
ﬁle, but the greater spontaneity that this
regimen can give to their sex life. Chronic
usage breaks the associative relationship
between taking a medication and having
sex 1 h later, which is one of the most
frustrating disadvantages of the on-
demand regimen.
Because of its pharmacokinetic pro-
ﬁle,tadalaﬁlisprobablythemoresuitable
medication for long-term use due to its
pharmacokinetic properties. The plasma
levels of tadalaﬁl taken daily are higher
than those obtained when taken on-
demand (37).
Regardless of its enormous potential,
the concept of daily oral treatment with
PDE5 inhibitors has been received with
some skepticism by several clinical inves-
tigators. Some key questions and con-
cerns have to be answered—namely,
tolerability, tachyphylaxis, and safety in
those patients who suffer from multiple
comorbidities—before this new treat-
ment regimen will be widely accepted.
CONCLUSIONS — Theuniquemech-
anism of action and high efﬁcacy of PDE5
inhibitorshasgeneratedimmenseinterest
among researchers dealing with sexual
dysfunction. From the launch of silde-
naﬁl, which occurred 10 years ago, a
new focus for basic and clinical research
had emerged regarding the safety proﬁle
and effect on other organs (vascular, pul-
monary, and urinary system) of PDE5 in-
hibitors because of their potential to treat
other chronic diseases. Moreover, use of
PDE5 inhibitors, which have been estab-
lished as an efﬁcacious and safe class of
drugs when prescribed to most men with
ED, restored sexual function to normal.
One of the major breakthroughs recently
achievedisprobablytheaccumulatingev-
idence that chronically administered
PDE5 inhibitors can improve endothelial
and sexual function. Daily treatment with
PDE5 inhibitors is now the preferred
method of treatment in several groups of
men with ED due to radical prostatec-
tomyandwithsevereendothelialandvas-
cular dysfunction such as diabetes. This
treatmentregimenhasalsobeenshownto
beneﬁt younger men, in whom this new
treatmentapproachisabletorestoretheir
sexual habits to normal, thereby remov-
ing the stigma of having a disease. Never-
theless, lack of knowledge regarding
detailed mechanisms, safety and tolera-
bility concerns, and costs may prevent a
broad application of this regimen.
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